Mural To Not Progress Platinum-Resistant Ovarian Cancer Trial To Final Analysis, Stock Down

(RTTNews) - Mural Oncology plc (MURA), Tuesday announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck's (MRK) Keytruda in patients with platinum-resistant ovarian cancer will not progress to final analysis.

The decision comes as the combination treatment failed to achieve a statistically significant improvement in overall survival versus investigator's choice chemotherapy alone.

Based on this pre-specified interim analysis, the company believe that the study is highly unlikely to achieve success at the final analysis.

Meanwhile, the interim analysis of ARTISTRY-7 showed that the safety profile of nemvaleukin was generally consistent with previously reported data.

The company stated that it remains on track to share topline results from potentially registrational, phase 2 trial in mucosal melanoma, ARTISTRY-6, Cohort 2, evaluating nemvaleukin monotherapy in the second quarter of 2025.

In the pre-market hours, Mural's stock is trading at $2.82, down 26.37 percent on the Nasdaq.